Owlstone Medical

They have a platform technology, where regardless of the application, the hardware remains largely the same, and the application is enabled through software. They are a profitable business with existing contracts, sales and market penetration in multi-billion dollar markets (military, industrial, medical). Owlstone currently has Department of Defense (DoD) funding to evolve their technology into a hand-held device that will deliver the highest level of sensitivity and selectively ever achieved in a portable instrument. Even though this hand-held product is about to change the capability of chemical detection in multi-billion dollar markets ranging from Military to Oil & Gas, the potential for their technology goes well beyond the current market expectations for hand-held point detectors. Peer-reviewed research confirms that cancer and other major diseases can be diagnosed early by detecting chemicals in breath and bodily fluids. Through Owlstone Medical, they aim to become the global leader in non-invasive diagnostics for cancer, infectious disease and inflammatory disease. They have an established pipeline of medical applications, including multi-billion dollar opportunities in colon cancer and lung cancer screening. Initial clinical trials have been completed in colon cancer and £1M contract has been received from UK National Health Service (NHS) for the LuCID lung cancer trials. The full potential for Owlstone is the development of a standalone system that will fit in the palm of your hand and integrate into a cell phone. When this happens, Owlstone will have evolved from a company that is delivering chemical detection products at the point of need, to a business that is delivering chemical data, anywhere. Fully miniaturized and cost optimized, their system will allow for pervasive deployment: real time chemical data will be available in every home, vehicle and street corner.

show less